a multicentre phase IV study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed HIV-infected patients undergoing bariatric suregery.

Inclusion Criteria:

• HIV-infected
• VL suppressed <40c/ml for at least 6 months, blips are allowed
• planned to have bariatric surgery (gastric bypass or gastric sleeve)
• Able to sign informed consent
• Age > or equal to 18 years
• Using doravirine for at least 4 weeks prior to BS with VL < 40 copies/mL prior to the surgery

Exclusion Criteria:

• History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation
• Requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine
• Has significant hypersensitivity or other contraindication to doravirine
• Creatinine clearance <40 ml/min
• Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C)
• Pregnancy or planning to be pregnant during first 6 months postbariatric surgery.